To the full analysis
Teladoc Health stock: growth
TDOCTeladoc Health reported $2.53B in revenue for fiscal 2025, down 1.5% on the prior year, up 18.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
49.7%
per year from 2013 to 2025, per share 28.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2013 | |
|---|---|---|---|
| Revenue | 18.3% | 41.7% | 49.7% |
| Revenue per share | 3.5% | 14.0% | 28.3% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2013 | $19.91M | −$6.02M | −$7.35M |
| 2014 | $43.53M | −$17.04M | −$13.09M |
| 2015 | $77.38M | −$58.02M | −$55M |
| 2016 | $123.16M | −$74.22M | −$55.21M |
| 2017 | $233.28M | −$106.78M | −$39.96M |
| 2018 | $417.91M | −$97.08M | −$13.27M |
| 2019 | $553.31M | −$98.86M | $18.97M |
| 2020 | $1.09B | −$485.14M | −$79.55M |
| 2021 | $2.03B | −$428.79M | $185.46M |
| 2022 | $2.41B | −$13.66B | $172.81M |
| 2023 | $2.6B | −$220.37M | $193.67M |
| 2024 | $2.57B | −$1B | $282.89M |
| 2025 | $2.53B | −$200.32M | $285.46M |
Revenue by region
Where Teladoc Health, Inc. generates its revenue.
- United States82%
- Outside the US18%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| United States | $2.24B | $2.16B | $2.07B | 81.9% |
| Outside the US | $364.88M | $409.62M | $458.24M | 18.1% |
| Total revenue | $2.6B | $2.57B | $2.53B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.